EUCTR2018-001320-19-GB进行中（未招募）1 期
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject (or their legally authorized representative or guardian) will sign and date an informed consent form (ICF) and, where applicable, an assent form.
- •2. Subjects 12 to 35 years of age, inclusive on the date of informed consent.
- •3. Documented ßS/ßS or ßS/ß0 genotype. Subjects can be enrolled based on historical genotype results, but confirmation of genotype is required before busulfan conditioning. The ß0 genotypes are defined using the HbVar Database.
- •4. Subjects with severe SCD. Severe SCD is defined by the occurrence of at least 2 of the following events per year during the 2-year period before screening, while receiving appropriate supportive care (e.g., pain management plan, HU):
- •Acute pain events that requires a visit to a medical facility and
- •administration of pain medications (opioids or intravenous [IV] nonsteroidal
- •anti-inflammatory drugs [NSAIDs]) or RBC transfusions
- •Acute chest syndrome, as indicated by the presence of a new
- •pulmonary infiltrate associated with pneumonia-like symptoms, pain, or fever
- •Priapism lasting >2 hours and requiring a visit to a medical facility
- •Splenic sequestration, as defined by an enlarged spleen, left upper
- •quadrant pain, and an acute decrease in hemoglobin concentration of =2 g/dL.
- •Historical severe VOCs will be adjudicated by the Endpoint Adjudication Committee (EAC).
- •5. Normal transcranial Doppler (TCD) velocity (time-averaged mean of the maximum velocity [TAMMV] <170 cm/sec) in the middle cerebral artery (MCA) and the internal carotid artery (ICA) for subjects 12 to 16 years of age.
- •6. Karnofsky performance status of =80% for subjects =16 years of age or Lansky performance status of =80% for subjects <16 years of age.
- •7. Eligible for autologous stem cell transplant as per investigator’s judgment.
- •8. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at least 1 ovary, and is less than 1 year postmenopausal) must agree to use acceptable method(s) of contraception from consent through at least 6 months after CTX001 infusion.
- •9. Male subjects of reproductive capacity must agree to use effective contraception from start of mobilization through at least 6 months after CTX001 infusion
- •10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.
- •11. Willing to participate in the long-term follow-up study (Study VX18-CTX001-131), after completion of this study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 5
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. An available 10/10 human leukocyte antigen (HLA)-matched related donor.
- •2. Prior Hematopoietic Stem Cell Transplant (HSCT).
- •3. Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the investigator.
- •4. White blood cell (WBC) count <3 × 109/L or platelet count <50 × 109/L, not related to hypersplenism per investigator judgment.
- •5. Treatment with regular RBC transfusions that, in the opinion of the investigator, cannot be interrupted after engraftment.
- •6. Subjects with history of alloimmunization to RBC antigens and for whom the investigator anticipates that there will be insufficient RBC units available for the duration of the study.
- •7. More than 10 unplanned hospitalizations or emergency department visits related to SCD in the 1 year before screening that, in the opinion of the investigator, are consistent with significant chronic pain rather than acute pain crises.
- •8. HbF level >15.0%, irrespective of concomitant treatment with HbF-inducing treatments such as HU.
- •9. History of abnormal TCD (TAMMV =200 cm/sec) for subjects 12 to 18 years of age.
- •10. History of untreated Moyamoya disease or presence of Moyamoya disease at Screening that in the opinion of the investigator puts the subjects at the risk of bleeding.
- •11. History of a significant bleeding disorder.
- •12. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the subject. This may include, but is not limited to: history of relevant drug allergies; history of cardiovascular or central nervous system disease; history or presence of clinically significant pathology; history of mental disease; or history of familial cancer syndrome.
- •13. Any prior or current malignancy or myeloproliferative disorder or a significant immunodeficiency disorder.
- •14. Advanced liver disease, defined as
- •a. Alanine transaminase (ALT) >3 × the upper limit of normal (ULN) or direct bilirubin value >2.5 × ULN, or
- •b. Baseline prothrombin time (PT) (international normalized ratio [INR]) >1.5 × ULN, or
- •c. History of cirrhosis or any evidence of bridging fibrosis, or active hepatitis on liver biopsy
- •15. Baseline estimated glomerular filtration rate <60 mL/min/1.73 m2.
- •16. Lung diffusing capacity for carbon monoxide (DLco) <50% of predicted value (corrected for hemoglobin and/or alveolar volume).
- •17. Left ventricular ejection fraction (LVEF) <45% by echocardiogram.
- •18. Prior treatment with gene therapy/editing product.
- •19. Intolerance, contraindication, or known sensitivity to plerixafor or busulfan. Prior anaphylactic reaction with excipients of CTX001 product (dimethylsulfoxide [DMSO], dextran).
- •20. Positive for the presence of human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) (positive antigen/antibody AND nucleic acid tests [NAT]), hepatitis B virus (HBV) (positive Hepatitis B core antibody [HBcAb] AND NAT tests), syphilis (positive screening AND confirmatory tests), or hepatitis C virus (HCV; positive antibody [HCAb] AND NAT tests). Additional infectious disease markers should be obtained and tested as required by the local authority for the collection and processing of cellular therapy products. These additional tests (e.g., HTLV-1, HTLV-2, malaria, tuberculosis, toxoplasmosis, Trypanosoma cruzi, or West e virus) will be evaluated to determine overall impact to the subject and manufacturing
研究者
相似试验
招募中
1 期
Phase 1/2 Basket Study of MK-2870 in GI CancersCTIS2023-508703-21-00Merck Sharp & Dohme LLC139
进行中（未招募）
1 期
A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL)CTIS2023-505840-20-00Astrazeneca AB153
招募中
1 期
AGN-193408 SR in the treatment of open-angle glaucoma or ocular hypertensioOcular hypertensionOpen-angle glaucomaJPRN-jRCT2031220053Yamazaki Hayato84
进行中（未招募）
1 期
Study conducted to learn more about the safety and effects of CTX001 (the Study Therapy”) in patients with Severe Sickle Cell DiseaseMedDRA version: 20.0Level: PTClassification code 10043391Term: Thalassaemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2018-001320-19-ITVERTEX PHARMACEUTICALS INCORPORATED45
进行中（未招募）
1 期
An early study to test IMGN901 with carboplatin and etoposide for treating adult patients with certain types of cancer including small cell lung cancerPhase 2: small cell lung cancer (extensive-stage disease)MedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10041058 Term: Small cell carcinoma of the lung System Organ Class: 100000004864EUCTR2010-022950-17-GBImmunoGen, Inc181